Month: October 2018

Microbiotica Participates in Microbiome Panel Discussion at this year’s Bio-Europe®

From Startup https://www.microbiotica.com/home Link to Full Article: https://www.microbiotica.com/news/18/58/Microbiotica-Participates-in-Microbiome-Panel-Discussion-at-this-years-Bio-Europe.html Microbiotica Participates in Microbiome Panel Discussion at this year’s Bio-Europe® Cambridge, UK, 30 October 2018 – Microbiotica, a leading player in microbiome-based therapeutics, today announced that it will join the microbiome panel at this year’s BIO-Europe®, taking place in Copenhagen between 5-7

BrainStorm Announces Financial Results for the Third Quarter of 2018 and Provides a Corporate Update

From Startup Brainstorm Cell Therapeutics Link to Full Article: http://ir.brainstorm-cell.com/phoenix.zhtml?c=142287&p=irol-newsArticle&ID=2373875 Highlights Scientific Advances and Continued Progress for NurOwn® in ALS Towards U.S. FDA Approval; Following Successful FDA Pre-IND Meeting, BrainStorm will File an IND for NurOwn® in a Second Clinical Indication Conference Call and Webcast Today at 8:30am Eastern Time

Eidos Therapeutics to Host Conference Call and Webcast to Discuss Phase 2 Clinical Trial Results

From Startup Eidos Therapeutics Link to Full Article: http://ir.eidostx.com/news-releases/news-release-details/eidos-therapeutics-host-conference-call-and-webcast-discuss SAN FRANCISCO, Oct. 29, 2018 (GLOBE NEWSWIRE) — Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX) today announced that management will host a conference call and webcast to discuss the results of its Phase 2 clinical trial of AG10 in patients with transthyretin amyloidosis

Aptinyx to Present Preclinical Data on Novel NMDA Receptor Modulators for Pain and Cognition at the 48th Annual Meeting of the Society for Neuroscience

From Startup Aptinyx Link to Full Article: https://ir.aptinyx.com/news-releases/news-release-details/aptinyx-present-preclinical-data-novel-nmda-receptor-modulators EVANSTON, Ill., Oct. 29, 2018 (GLOBE NEWSWIRE) — Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced four upcoming poster presentations highlighting preclinical data on two N-methyl D-aspartate (NMDA) receptor modulators,

Aduro Presents Preclinical Data for Anti-APRIL Antibody BION-1301 for the Treatment of IgA Nephropathy at ASN Kidney Week 2018

From Startup Aduro Biotech Link to Full Article: BERKELEY, Calif., Oct. 26, 2018 (GLOBE NEWSWIRE) — Aduro Biotech, Inc. (NASDAQ: ADRO) today announced preclinical data for its first-in-class anti-APRIL antibody BION-1301 supporting its use in the treatment of IgA nephropathy (IgAN) at the American Society of Nephrology (ASN) Kidney Week

Eidos Therapeutics Receives Positive Opinion for Orphan Designation from the European Medicines Agency for AG10, a Potent Oral Stabilizer for the Treatment of Transthyretin Amyloidosis

From Startup Eidos Therapeutics Link to Full Article: http://ir.eidostx.com/news-releases/news-release-details/eidos-therapeutics-receives-positive-opinion-orphan-designation SAN FRANCISCO, Oct. 26, 2018 (GLOBE NEWSWIRE) — Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), announced today that the Committee for Orphan Medicinal Products (COMP) within the European Medicines Agency (EMA) adopted a positive opinion for the designation of Eidos’ product candidate, AG10, as

Axovant Announces Dosing of First Patient in Clinical Study of AXO-Lenti-PD, a Novel Gene Therapy for Patients With Parkinson’s Disease

From Startup Axovant Link to Full Article: http://investors.axovant.com/news-releases/news-release-details/axovant-announces-dosing-first-patient-clinical-study-axo-lenti Initial data from the first cohort expected in first half of 2019 BASEL, Switzerland, Oct. 25, 2018 (GLOBE NEWSWIRE) — Axovant Sciences (NASDAQ:AXON), a company developing innovative gene therapies for neurologic and neuromuscular diseases, today announced dosing of the first patient in